Overview: CD79b Flow Cytometry TestIntroduction: The CD79b Flow Cytometry Test detects CD79b markers to diagnose lymphoma, causing fatigue or weight loss. Following 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected lymphoma.
Other Names: CD79b Flow Assay, B-Cell Receptor Component Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: CD79b testing began in the 1990s with lymphoma research. Flow cytometry emerged in the 2000s, improving accuracy for marker detection.
Purpose: Diagnoses lymphoma, guides treatment, and monitors CD79b markers in patients with fatigue or weight loss.
Test Parameters: 1. CD79b
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or weight loss, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, weight loss, or history of lymphoma. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect CD79b markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD79b.
Clinical Significance: Positive CD79b expression suggests lymphoma, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers (e.g., CD19, CD20), or PET scan to confirm lymphoma.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
